Securities code: 600739 securities abbreviation: Liaoning Chengda Co.Ltd(600739) Announcement No.: pro 2022-015 Liaoning Chengda Co.Ltd(600739)
Announcement on the 2021 annual performance express of the company’s holding subsidiary Liaoning Chengda Co.Ltd(600739) Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Liaoning Chengda Co.Ltd(600739) (hereinafter referred to as “the company”) is the controlling shareholder of Liaoning Chengda Co.Ltd(600739) Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd. (hereinafter referred to as ” Liaoning Chengda Biotechnology Co.Ltd(688739) “). As of the disclosure date of this announcement, the company holds 227663764 shares of Chengda biology, accounting for 54.67% of its total share capital.
Liaoning Chengda Biotechnology Co.Ltd(688739) the performance express of 2021 is as follows:
1、 Main financial data and indicators in 2021
Unit: RMB
Increase / decrease range of the project in the same period of last year in the reporting period (%)
Total operating income 2088043469.78 1995575513.96 4.63
Operating profit 1022695250.19 1083082934.41 -5.58
Total profit 1030978302.67 1062916892.22 -3.00
Net profit attributable to owners of the parent company: 892490658.44 918193965.36 -2.80
Net profit attributable to the owner of the parent company after deducting non recurring profits and losses of 862518502.00 844543990.25 2.13
Basic earnings per share (yuan) 2.34 – 2.45 – 4.49
The weighted average return on net assets was 16.88% and 24.59%, down 7.71 percentage points
Increase / decrease range at the end of the reporting period (%)
Total assets 9792731456.06 4478317436.27 118.67
Owner’s equity attributable to the parent company 9352015548.09 4118145455.91 127.09
Share capital 416450000.00 374800000.00 11.11
Net assets per share attributable to the owner of the parent company: 22.46 10.99 104.37 yuan
Note: 1 The beginning amount of this report is the same as the end amount of the previous year legally disclosed.
2. The above financial data and indicators are filled in with consolidated statement data, but without audit, the final data are in Chengda
The data disclosed in the biological annual report in 2021 shall prevail.
3. If there is a tail difference in the above increase or decrease range data, it is caused by rounding.
2、 Description of operating performance and financial status
(I) operating conditions, financial conditions and main factors affecting operating performance during the reporting period
During the reporting period, Liaoning Chengda Biotechnology Co.Ltd(688739) achieved an operating revenue of 208843500 yuan, a year-on-year increase of 4.63%; The net profit attributable to the owners of the parent company was 892490700 yuan, a year-on-year decrease of 2.80%; The net profit attributable to the owner of the parent company after deducting non recurring profits and losses was 862518500 yuan, a year-on-year increase of 2.13%. The operating income of Chengda biology increased year-on-year, the net profit decreased slightly, and the net profit after deduction increased slightly, mainly due to the decrease of the fair value of Liaoning Chengda Biotechnology Co.Ltd(688739) investment compared with the same period of the previous year.
At the end of the reporting period, Liaoning Chengda Biotechnology Co.Ltd(688739) total assets were 9792.7315 million yuan, an increase of 118.67% over the beginning of the period; The owner’s equity attributable to the parent company was 9352.0155 million yuan, an increase of 127.09% over the beginning of the reporting period; The share capital was 416.45 million yuan, an increase of 11.11% over the beginning of the reporting period. Liaoning Chengda Biotechnology Co.Ltd(688739) the operating performance in this period is stable and the financial situation is good.
(II) description of the main reasons for the increase or decrease of more than 30% of the relevant items in the above table
At the end of the reporting period, Liaoning Chengda Biotechnology Co.Ltd(688739) total assets, owner’s equity attributable to the parent company and net assets per share attributable to the owner of the parent company increased by 118.67%, 127.09% and 104.38% respectively compared with the beginning of the reporting period, mainly due to the initial public offering of Liaoning Chengda Biotechnology Co.Ltd(688739) shares during the reporting period, with a net raised capital of 4341.3794 million yuan.
3、 Risk tips
The main financial data contained in the announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data are subject to the data disclosed in the annual report of Liaoning Chengda Biotechnology Co.Ltd(688739) 2021. Please pay attention to the investment risks.
It is hereby announced.
Liaoning Chengda Co.Ltd(600739) board of directors February 19, 2022
